Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Deal Watch: Qpex Partners Its Experimental Antibiotics With Brii In Greater China

Executive Summary

Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.

You may also be interested in...



Multiple Alliances Expand Brii’s Commitment To Anti-Infectives

China-focused venture goes against tide by acquiring anti-infective assets via multiple deals that will build out its pipeline in an area deprioritized by big pharma.

Need For Partnering Won’t Change But Shape Might - BioJapan

While industry participants at BioJapan expect big pharma to continue to seek external partnerships and acquisitions to bolster pipelines, the technology and countries involved in such alliances look set to change.

Dainippon’s Cynata Quest Falls Through As Sides Remain Apart

Japanese firm backs off potential acquisition of Australian cell therapy venture after the two sides fail to agree on deal terms.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC126061

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel